Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

Tomoki EbataS HiranoM KonishiK UesakaY TsuchiyaM OhtsukaY KaneokaM YamamotoY AmboY ShimizuF OzawaA FukutomiM AndoY NimuraM Naginonull null

Published in: The British journal of surgery (2018)

The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).

Keyphrases

papillary thyroid
locally advanced
squamous cell
lymph node
early stage
lymph node metastasis
squamous cell carcinoma